ACBI3 molecule offers new hope for targeting KRAS mutations in cancer

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

In absence of Roe v. Wade, an abortion doctor dwells on all the patients she does not see

Last year, just a few months after the Supreme Court’s reversal of Roe v. Wade ended the constitutional right to abortion in the United States,

June 23, 2023

Managing Non-Transfusion-Dependent Thalassemia Presents Challenges

An essential factor in distinguishing thalassemia phenotypes is transfusion dependence. While beta-thalassemia major requires life-long blood transfusions for survival, non-transfusion-dependent thalassemia usually only requires occasional

January 22, 2025

US DoD grants $2.3m to Immuron for military version of anti-diarrhoeal Travelan – Pharmaceutical Technology

The DoD states that infectious diarrhoea is the most common illness that US troops deployed overseas experience. Image credit: Shutterstock / Andrew Angelov. Immuron Limited

August 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.